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Abstract
Background: There is absence of specific biomarkers and an incomplete understanding of the pathophysiology of
exudative age-related macular degeneration (AMD).
Methods and Findings: Eighty-eight vitreous samples (73 from patients with treatment naı¨ve AMD and 15 control samples
from patients with idiopathic floaters) were analyzed with capillary electrophoresis coupled to mass spectrometry in this
retrospective case series to define potential candidate protein markers of AMD. Nineteen proteins were found to be
upregulated in vitreous of AMD patients. Most of the proteins were plasma derived and involved in biological (ion)
transport, acute phase inflammatory reaction, and blood coagulation. A number of proteins have not been previously
associated to AMD including alpha-1-antitrypsin, fibrinogen alpha chain and prostaglandin H2-D isomerase. Alpha-1-
antitrypsin was validated in vitreous of an independent set of AMD patients using Western blot analysis. Further systems
biology analysis of the data indicated that the observed proteomic changes may reflect upregulation of immune response
and complement activity.
Conclusions: Proteome analysis of vitreous samples from patients with AMD, which underwent an intravitreal combination
therapy including a core vitrectomy, steroids and bevacizumab, revealed apparent AMD-specific proteomic changes. The
identified AMD-associated proteins provide some insight into the pathophysiological changes associated with AMD.
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Introduction
Age dependent alterations of the retinal pigment epithelium
(RPE) and its basal membrane, called Bruchs membrane, are
widely accepted as the main pathophysiological reason for age-
related macular degeneration (AMD) and is thus the leading cause
of blindness in people over the age of 60 years in industrialized
countries [1]. The upregulation of vascular endothelial growth
factor (VEGF) and the development of a choroidal neovascular-
ization (CNV) are the blueprint for the conversion to the exudative
or wet AMD form. Our understanding today of the disease and
the interaction of intravitreal anti-VEGF treatment is thereby
coined and determined by clinical diagnostics, mainly optical
coherence tomography and fluorescein angiography. Since AMD
is a pure retinochoroidal disease, circulating in vivo biomarkers
such as HbA1c in the diagnosis and treatment of diabetes are still
absent for AMD. Samples from the human vitreous might best
qualify as a source of biomarkers for AMD due to the proximity to
the retina and the efflux of cytokines into the vitreous cavity [2].
However, most published protein analyses in exudative AMD
derive from experimental animal models, ex vivo samples or in vivo
from ocular anterior chamber aspirates (AC) with the incorporated
flaws [3,4,5,6]. Ecker et al. demonstrated, that cytokine and
growth factor levels from the AC do not reliably reflect those levels
found in the vitreous and thus it is questionable to assess the
activity of a purely retinochoroidal disease by examining an AC
aspirate [2,7,8]. But results from vitreous samples in AMD are
scarce and published data differs on patient selection, sampling
technique and analysis method [7,9,10,11,12,13,14,15].
Proteome analysis allows the simultaneous assessment of a large
number of proteins in a sample. Proteome analyses have been
performed in a variety of ocular diseases, including primary open-
angle glaucoma and cataract [16,17,18]. Further exploration of
vitreous protein profiles was performed even tough clinical factors,
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like consistency of the vitreous, length of the eye, attachment of the
posterior hyaloid are to date neglected in the literature [19].
Especially in the context of wet AMD the current proteomic data
on vitreous or aqueous humor are incomplete.
Capillary electrophoresis coupled to mass spectrometry (CE-
MS) is a powerful and very reproducible technology platform with
known performance characteristics [20]. This automated, sensi-
tive, fast proteome analysis technique [21] using CE as a front-end
fractionation coupled to mass spectrometry, separates peptides and
small proteins (,20 kDa) based on migration in the electrical field
with high resolution in a single step. It enables analysis of
thousands of peptides per sample using a sub-microliter sample
volume and it has been used in numerous clinical biomarker
studies, mostly examining urine as the specimen of interest
[22,23].
In this pilot study, we performed a bottom-up analysis combing
the reproducibility of CE-MS for selection of candidate marker
proteins, and LC-MS/MS for sequence identification of these
markers in vitreous of 73 AMD patients and controls. This led to
the identification of a number of candidate proteins not previously
shown to be involved in AMD. Systems biology analysis of the
data suggested an increase in immune response, complement
activation and protease activity to be involved in the pathophys-
iology of AMD.
Material and Methods
Sampling and patient characteristics
Vitreous samples were acquired at the beginning of an
intravitreal combination treatment for wet AMD, which involved
a 23-gauge core vitrectomy of at least 4 cc vitreous, before the
application of bevacizumab, triamcinolone, and dexamethasone
[22]. The same surgical technique was applied for the removal of
idiopathic vitreous floaters, substituting balanced salt solution (BSS
Plus, Alcon, Freiburg, Germany). This study adhered to the
Declaration of Helsinki and was approved by the Investigational
Review Board of the Goethe University. Written informed consent
was obtained from all participants, explaining the risks and
benefits of the treatment (the advantage of a combination
treatment for wet AMD rather than with anti-VEGF monotherapy
is summarized here [24,25,26]; the vitreous samples would
otherwise have been disposed).
A total of 88 undiluted and previously untreated (any intraviteal
drug application) samples were analyzed (Table 1). The 73 AMD
samples came from 73 patients (50 women 23 men) with a mean
age 77.8 6 8.9 years (standard deviation). Sixteen of the 73
patients had a hemorrhagic CNV; 37 had an active CNV (10 with
signs accompanying bleeding); 13 had a CNV and greater than
80% fibrous staining in the fluorescein angiography (FA); and 7
had a CNV-associated RPE detachment and no intraretinal fluid.
These classifications were assigned after a complete ocular
examination, which included a slit-lamp biomicroscopy, indirect
ophthalmoscopy, color fundus photography, spectral domain
optical coherence tomography (3D-OCT 2000, Topcon, Willich,
Germany), and FA. Patients with previous intravitreal anti-VEGF
treatment, including intraocular steroids, or systemic diabetes,
nephropathy or uncontrolled hypertension were excluded. Patients
with any other compromising ocular condition, such as diabetic
retinopathy or uveitis, were also considered ineligible for this
study.
All patients were recruited from the retina clinic of the
department of ophthalmology from the Goethe University in
Frankfurt am Main in Germany. Vitreous samples from 15
patients with idiopathic floaters (8 women, 7 men; mean age 60 6
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16 years) served as controls. All vitreous samples were stored at 2
80uC.
Tryptic digestion of vitreous
A 10-mL portion of the thawed sample was diluted with 90 mL
0.1% SDS, 20 mM DTT, and 0.1 M TrisHCl (pH = 7.6). The
sample was sonicated at room temperature for 30 minutes to
decrease viscosity and break up hyaluronic polymers contained in
the vitreous humor. This was followed by denaturation at 95uC for
3 min. Samples were subsequently incubated with 80 mM
Iodoacetamide at room temperature for 30 min in the absence
of light, followed by the addition of ammonium bicarbonate buffer
solution (300 mL, 50 mM) and applied to NAP-5 columns
equilibrated in 50 mM ammonium bicarbonate buffer solution.
Twenty mg of Lyophilized trypsin was dissolved in 50 mL of
buffer solution provided with the lypholized product. Two mL of
this solution was added to the desalted sample. Trypsin digestion
was carried out overnight at a temperature of 37uC. Subsequently
the samples were lyophilized, stored at 4uC and resuspendend in
HPLC-grade H2O shortly before mass spectrometry analysis.
CE-MS analysis
CE-MS analysis was performed as described by Theodorescu et
al [27]. A P/ACE MDQ capillary electrophoresis system (Beck-
man Coulter, Brea, CA) was linked online to a micro-TOF MS
(Bruker Daltonik, Leipzig, Germany). The sprayer (Agilent
Technologies, Santa Clara, CA) interfacing the CE and MS was
grounded and the interface potential was adjusted to 24.5 kV.
Signals were recorded at an m/z range of 350–3000. The
detection limit of the TOF-Analyzer is in the range of 1 fmol [27].
Data processing
Analysis of raw CE-MS data was carried out using Mosaiques-
Visu [28]. MosaiquesVisu uses isotope identification and conju-
gated mass detection for mass deconvolution. Signals with a signal-
to-random noise ratio.4 and charge .1 were used. Mass spectral
ion peaks from the same molecule at different charge states were
deconvoluted into a single mass.
In total, 292 signals for mass and CE-time with a frequency $
35% could be determined that served as reference signals for
normalization of peptide CE-time and mass using linear regres-
sion. For signal intensity normalization, 22 internal standards were
selected that were consistently detected in vitreous samples
(average frequency 83%) and that did not appear to be
significantly associated with the disease. This signal intensity
normalization using internal standards has been shown to be a
reliable method to address both analytical and biological variances
in biological samples [29].
The normalized peptides were deposited, matched, and
annotated in a Microsoft SQL database. Peptides were considered
identical when deviation of mass was , 650 ppm for an 800 Da
peptide. The mass deviation was adjusted by an increase in size of
up to 675 ppm for 15 kDa. Peptides were considered identical if
the CE-migration time window did not exceed 2–5%, continu-
ously increasing between 19 and 50 min. A number of peptides
were only sporadically observed. To eliminate such low relevance
peptides, all peptides that appeared only once were removed and
were not considered for further analysis.
Tandem mass spectrometry (MS/MS) sequencing
For MS/MS analysis five lyophilized, tryptic-digested randomly
selected vitreous samples were dissolved in 15 mL distilled water.
Fractionation was carried out according to Metzger et al. [30]
using a Dionex Ultimate 3000 Nano LC System (Dionex,
Camberly, UK). After loading (5 ml) onto a Dionex 0.1620 mm
5 mm C18 nano trap column at a flowrate of 5 ml/min in 98%
0.1% formic acid and 2% acetonitrile, sample was eluted onto an
Acclaim PepMap C18 nano column 75 mm615 cm, 2 mm 100 A˚
at a flow rate of 0.3 ml/min. The trap and nano flow column were
maintained at 35uC. The samples were eluted with a gradient of
solvent A:98% 0.1% formic acid, 2% acetonitrile verses solvent B:
80% acetonitrile, 20% 0.1% formic acid starting at 1% B for 5
minutes rising to 20% B after 90 min and finally to 40%B after
120 min. The column was then washed and re-equilibrated prior
to the next injection. The eluant was ionized using a Proxeon nano
spray ESI source operating in positive ion mode into an Orbitrap
Velos FTMS (Thermo Finnigan, Bremen, Germany). Ionization
voltage was 2.6 kV and the capillary temperature was 200uC. The
mass spectrometer was operated in MS/MS mode scanning from
380 to 2000 amu. The top 20 multiply charged ions were selected
from each scan for MS/MS analysis using HCD at 40% collision
energy. The resolution of ions in MS1 was 60,000 and 7,500 for
HCD MS2. The MS data and the human, non redundant
database IPI were matched using the SEQUEST software.
Trypsin was used as the enzyme while screening for proteins.
Hydroxylated proline from collagen fragments and oxidation of
methionine were accepted as variable modifications and carba-
midomethylated cystein as fixed modification. A maximal mass
deviation of 10 ppm for MS and 0.8 Da for MS/MS was
accepted. Only proteins represented by a minimum two peptides
were accepted in LC-MS/MS analysis. The sequences were
matched to the detected CE-MS data as described by Zu¨rbig et al
[19]. Although in this matching procedure the LC retention time
can not be used, CE-MS data generate an additional parameter
that can be used in this matching procedure, which is the charge of
the peptides (at low pH, the condition in which peptides are
analysed by CE-MS). Therefore, even when having identical or
very close masses in the LC-MS/MS analysis, discrimination
between peptides with similar masses can be performed on the
basis of their charge. This is due to the fact that the number of
basic and neutral polar amino acids of peptide sequences distinctly
correlates with their CE-MS migration time/molecular weight
coordinates. In nearly all cases this allows linking a unique LC-
MS/MS peptide to a CE-MS peptide as shown previously [19].
CE-MS peptides with sequencing information were combined
for each protein. Protein abundance was calculated as the average
of all normalized CE-MS peptide intensities for the given protein.
Mean protein abundance in the case group was compared to the
mean protein abundance in the control group. Protein entries
were mapped to the SwissProt database using either the mapping
service provided by UniProt or via Blast searching (web.expa-
sy.org/blast/) and merged according to the SwissProt names.
Biomarker definition
Candidate AMD biomarkers were defined by examination of
differences in frequency and signal intensity of the proteins
between the AMD patients and controls. Mean CE-MS based
protein signal intensity was used as a measure for relative
abundance. Statistical analysis was performed using Graph Pad
Prism 5.0 software. A F-test was performed to test for data
distribution. When data were normally distributed, a parametric t-
test was performed; otherwise, the statistical analysis was
performed using a Mann-Whitney test or Wilcoxon signed rank
test. Multiple hypotheses testing correction was performed using
the Benjamini-Hochberg test for false discovery rate [31].
Proteomics in Wet AMD
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Bioinformatics analysis
Gene ontology (GO) keyword-cluster analysis was done using
CytoScape (www.cytoscape.org) and the ClueGO plug-in, where
statistically significant molecules with p-values of less than 0.05
were compared. The interactome analysis was performed using
CytoScape and the Michigan Molecular Interactor plug-in
(mimi.ncibi.org). Full interactome analysis was carried out by
connecting molecules through neighboring proteins, whereas the
condensed protein-protein interaction analysis was performed by
searching for direct associations. The paradigm of this analysis is
that molecules with similar cellular involvement tend to cluster
together through physical interactions, such as molecular ma-
chines. The disease analysis is based on known or inferred genetic
disorders associated with mutations of specific genes using the
Online Mendelian Inheritance in Man database for data mining.
An additional pathway analysis was carried out using the Kyoto
encyclopedia of genes and genomes (KEGG) database, where
KEGG accession numbers of the statistically significant molecules
were used for mapping-queries. Additionally, disease-specific
descriptions were retrieved from the Online Mendelian Inheri-
tance in Man (OMIM) database as well as the UniProt database.
Cellular expression data was also obtained from the latter
resource.
Western blot analysis
To determine the protein levels of Transthyretin, Apolipopro-
tein A 1, Alpha-1 Antitrypsin, Serotransferrin and Retinol-binding
protein 3 we obtained vitreous fluid as described above. The
extracted proteins (20 ml/5 mg protein) were loaded and subjected
to 12.5% sodium dodecyl sulfate-polyacrylamide gel electropho-
resis (SDS-PAGE) for 30 min at 100 V and then 90 min at 150 V
and subsequently transferred onto nitrocellulose membranes using
Trans-Blot Turbo Transfer System (Bio-Rad, Hercules, CA,
USA). The membranes were blocked for 1 h at room temperature
in blocking buffer consisting of 5% BSA in PBS and 0.1% Tween.
This was followed by a 465 min washing procedure in Wash
Buffer (PBS + 0.1% Tween). Blots were incubated with primary
antibodies (Santa Cruz Biotechnology) for 2 h at 4uC followed by
incubation with secondary antibodies conjugated to horseradish
peroxidase (Santa Cruz Biotechnology) for 2 h at 4uC. Blots were
visualized with enhanced chemiluminescence (Amersham Biosci-
ences, Piscataway, NJ, USA).
Results
Sequencing of tryptic peptides
Using LC-MS/MS, 622 of the tryptic peptides detected with
CE-MS could be identified. The mass of sequenced peptides
ranged between 804 and 3953 Da. These tryptic peptides
corresponded to 97 different proteins in vitreous humor (Table 2).
Definition of AMD-specific proteins
Figure 1 is a descriptive presentation of the study setup and
findings. All samples were analysed by CE-MS. Next, for statistical
analysis, CE-MS detected tryptic peptides were matched to the
sequences identified by LC-MS/MS. 622 of the CE-MS detected
peptides could be identified by their amino acid sequence. These
peptides were combined to 97 proteins as described [29] and this
protein distribution was statistically analysed. 19 proteins displayed
significant differential abundance in vitreous (Table 3). All
proteins with a p-value of ,0.05 were found to be upregulated
in the AMD population.
Validation using Western blot analysis
Western blot analysis was used to verify the findings in table 3
on 5 randomly selected proteins for which antibodies were readily
available, using a new but small set of AMD and control samples
(n = 4/group). Four out of the 5 proteins analyzed did not display a
significant variation, but the fold increases for apolipoprotein A1
and transthyretin suggested increased expression in vitreous of
AMD patients similarly to what observed in the intial CE-MS
experiments. The absence of significance is most probably due to
the small patient population used for in the validation experiments
(Table 4 and Figure 2). However, we validated increased alpha-
1-antitrypsin abundance in vitreous of AMD patients (p = 0.02).
Gene enrichment and pathway analysis
The 19 proteins with differential abundance in AMD were
analyzed for their biological process, molecular function and the
cellular component. GO cluster analysis using ClueGO showed
that these proteins are primarily involved in biological (ion)
transport and secretion/exocytosis (platelet degranulation (ALB,
TF, APOA1, SERPINA1, HRG, FGA) and fatty acid binding
(RBP3, ALB, PTGDS)), protease inhibitor activity (ITIH1,
SERPINA1, SERPINC1, HRG), and processes involving hydro-
gen peroxide (GPX3, HP). These molecules consist mostly of
secreted proteins (Figure 3A).
A global interactome analysis of the statistically relevant
proteins using the Michigan Molecular Interactor plug-in, which
mines data from protein-protein, protein-gene, gene-gene, mole-
cule-pathway, and molecule-keyword associations, resulted in a
densly interconnected network (Figure 3B). This expanded
network of 54 proteins, including molecules known to be
associated with the query molecules, consists of an immunoglob-
ulin-cluster and complement activation (containing IGHA1,
IGKC, IGHG1, IGLC2, AHSG, ITIH1, and FGA), suggesting
inflammation and acute phase response processes being activated
in the original source tissue, and processes including cell adhesion,
lipid metabolism (RBP3, PTGDS), transport (APOA1, ALB,
TTR, TF), anti-apoptosis (GPX3), and proteolysis (proteases (HP)
and protease inhibitors (HRG, SERPINA1 and SERPINC1)).
Inter-linking molecules suggest an involvement of transcriptional
elements such as ONECUT and HNF1A/4A, which are
modulators of genes involved in lipid metabolic processes, blood
coagulation
Analysis of the condensed network of direct interactions
between the 19 proteins shows the immunoglobulin cluster
containing IGLC2, IGKC, and IGHG1, binary interactions
between ALB and ITIH1, and between HRG and FGA, as well
as a binary cluster of APOA1 and TTR. The latter suggests that
the peroxisome proliferator-activated receptor (PPAR) signaling
pathway is perturbed in AMD through an association with TTR
and fibrils (Figure 3B).
Data mining of the Online Mendelian Inheritance in Man
database by associated disease clustering showed one relevant
cluster consisting of APOA1 (cataract formation) and TTR (fibril
formation (neurodegenerative)). The same components were also
found by association using a similar approach to mine the disease
entries in the KEGG database, where the common denominator
was found as familial amyloidosis (KEGG disease entry H00845),
linking it to the complement and coagulation cascade (Figure 3C).
Furthermore KEGG pathway analysis also suggested an involve-
ment of arachidonic acid metabolism to be modulated in AMD.
Literature mining also revealed a semantic link between cataract
formation and up-regulated levels of GPX3 in the lens.
Proteomics in Wet AMD
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Table 2. Proteins in vitreous humor detected by CE-MS and identified by LC-MS/MS analysis.
Protein UniProt*
Peptide
number** Coverage*** (%)
Peptide number
control****
Peptide
number
case****
Actin, aortic smooth muscle P62736 1 3 0 1
Afamin P43652 2 4 2 2
Angiotensinogen P01019 1 2 1 1
Alpha-1-acid glycoprotein 1 P02763 7 27 7 7
Alpha-1-acid glycoprotein 2 P19652 3 15 3 3
Alpha-1-antitrypsin P01009 20 52 20 20
Alpha-1B-glycoprotein P04217 5 11 5 5
Alpha-2-HS-glycoprotein P02765 4 16 4 4
Alpha-2-macroglobulin P01023 13 10 9 13
Alpha-crystallin B chain P02511 2 14 1 2
Amyloid-like protein 2 Q06481 2 4 2 2
Antithrombin-III P01008 10 23 4 10
Apolipoprotein E P02649 13 43 12 13
Apolipoprotein A-I P02647 18 63 16 18
Apolipoprotein A-II P02652 4 41 4 4
Apolipoprotein A-IV P06727 10 30 5 10
Beta-2-microglobulin P61769 2 17 1 2
Beta-crystallin B2 P43320 11 50 11 11
Chitinase-3-like protein 1 P36222 1 3 1 1
Ceruloplasmin P00450 14 20 12 14
Clusterin P10909 12 31 11 12
Collagen alpha-1(I) chain P02452 2 1 2 2
Collagen alpha-1(II) chain P02458 38 27 35 36
Collagen alpha-1(III) chain P02461 1 2 1 1
Collagen alpha-1(IX) chain P20849 5 9 4 5
Collagen alpha-1(V) chain P20908 4 1 2 3
Collagen alpha-1(XI) chain P12107 5 3 5 5
Collagen alpha-1(XII) chain Q99715 1 1 1 1
Collagen alpha-1(XXII) chain Q8NFW1 1 1 1 1
Collagen alpha-1(XXIII) chain Q86Y22 1 3 1 1
Collagen alpha-1(XXVIII) chain Q2UY09 1 2 0 1
Collagen alpha-2(IX) chain Q14055 4 6 4 4
Collagen alpha-2(XI) chain P13942 1 2 1 1
Collagen alpha-3(IX) chain Q14050 5 7 5 5
Complement C3 P01024 32 23 23 32
Complement C4-B P0C0L5 11 7 10 11
Complement factor B P00751 5 7 3 5
Alpha-crystallin A chain P02489 3 19 3 3
Cathepsin D P07339 3 11 3 3
Cystatin-C P01034 2 18 2 2
Dermcidin P81605 3 23 1 3
Dickkopf-related protein 3 Q9UBP4 6 22 6 6
Double-strand break repair protein MRE11A P49959 1 2 0 1
Fibrinogen alpha chain P02671 4 6 3 4
Fibrinogen beta chain P02675 1 3 1 1
Gelsolin P06396 1 2 0 1
Glutathione peroxidase 3 P22352 4 23 3 4
Haptoglobin P00738 13 24 10 13
Proteomics in Wet AMD
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Table 2. Cont.
Protein UniProt*
Peptide
number** Coverage*** (%)
Peptide number
control****
Peptide
number
case****
Hemoglobin subunit beta P68871 1 9 1 1
Hemopexin P02790 14 29 12 14
Heparin cofactor 2 P05546 1 2 1 1
Histidine-rich glycoprotein P04196 2 4 2 2
Ig alpha-1 chain C region P01876 3 8 3 3
Ig alpha-2 chain C region P01877 4 8 2 2
Ig gamma-1 chain C region P01857 11 37 11 11
Ig gamma-3 chain C region P01860 4 12 3 4
Ig heavy chain V-III region GAL P01781 2 8 1 2
Ig heavy chain V-III region TRO P01762 1 6 1 1
Ig kappa chain V-I region EU P01598 1 17 1 1
Ig kappa chain V-III region SIE P01620 1 17 1 1
Ig kappa chain C region P01834 5 80 4 5
Ig lambda-2 chain C regions P0CG05 3 42 3 3
IgGFc-binding protein Q9Y6R7 4 1 4 4
Immunoglobulin lambda-like polypeptide 5 B9A064 1 9 1 1
Inter-alpha-trypsin inhibitor heavy chain H1 P19827 3 4 3 3
Inter-alpha-trypsin inhibitor heavy chain H4 Q14624 2 2 1 2
Keratin, type I cytoskeletal 10 P13645 18 34 16 18
Keratin, type I cytoskeletal 14 P02533 3 7 2 3
Keratin, type I cytoskeletal 9 P35527 7 14 6 7
Keratin, type II cytoskeletal 1 P04264 18 26 17 17
Keratin, type II cytoskeletal 2 epidermal P35908 3 6 3 3
Keratin, type II cytoskeletal 5 P13647 1 2 1 1
Keratin, type II cytoskeletal 6A P02538 1 2 1 1
Keratin, type II cytoskeletal 6B P04259 2 4 2 2
Kininogen-1 P01042 4 5 2 4
Leucine-rich alpha-2-glycoprotein P02750 1 3 0 1
Opticin Q9UBM4 3 9 2 3
Osteopontin P10451 7 34 7 7
Pigment epithelium-derived factor P36955 12 31 11 12
Plasminogen P00747 1 1 0 1
Prostaglandin-H2 D-isomerase P41222 4 21 4 4
Protein Jade-2 Q9NQC1 1 1 1 1
Protein S100-A7 P31151 1 11 1 1
Protein S100-A9 P06702 2 18 2 2
Prothrombin P00734 2 4 2 2
Retinol-binding protein 3 P10745 15 18 14 15
Ig kappa chain V-III region VG P04433 2 23 1 2
Plasma protease C1 inhibitor P05155 5 12 5 5
Serotransferrin P02787 44 55 43 44
Alpha-1-antichymotrypsin P01011 15 36 12 15
Serum albumin P02768 55 75 51 55
Complement C4-A P0C0L4 1 1 1 1
Titin Q8WZ42 1 0 0 1
Transthyretin P02766 7 63 7 7
Vitamin D-binding protein P02774 5 9 4 5
Vitronectin P04004 3 9 2 3
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Discussion
The aim of this pilot study was to test the hypothesis that specific
proteins in vitreous samples of patients with exudative AMD are
significantly associated with the disease and may lead to a better
understanding of the pathophysiology of the disease.
We initially set out to analyze native peptides from vitreous (top-
down strategy) with a mass of up to 20 kDa using CE-MS analysis.
However, this strategy did not result in satisfactory data, as a result
of high variability (Koss M et al. Proteomics in AMD; Poster
2927/A327 at the annual meeting of the Assiciation for Research
in Vision and Ophtalmology (AVRO), Ft.Lauderdale, USA in
2012). A possible reason for the large variation between the
measurements could be the presence of hyaluronic acid. Because
of the highly negative charge of its monomers, hyaluronic acid
reacts with positively charged proteins such as albumin to build up
polyelectrolyte complexes displaying low solubility [32]. Since the
top-down strategy failed to give the expected results, we changed
the strategy and in the current study employed trypsin digested
samples for proteome analysis of vitreous.
Using this bottom-up approach we could successfully analyze
the vitreous humor samples with CE-MS, including fragments of
proteins with molecular masses above 20 kDa. We identified a
total of 97 proteins, 19 of those significantly increased in AMD
patients. We selected 5 random proteins among these 19 for
validation by Western blot analysis. One protein (alpha-1-
antitrypsin) reached statistical significance while two others
(transthyretin and apoliprotein A1) displayed a non-significant
but increased abundance in AMD. The latter is most likely due to
the low number of patients in the validation set (n = 4/group) and
needs validation.
Most of the upregulated proteins in AMD patients are plasma
proteins. Our findings therefore may, to some degree, be
Figure 1. Study design and results.
doi:10.1371/journal.pone.0096895.g001
Table 2. Cont.
Protein UniProt*
Peptide
number** Coverage*** (%)
Peptide number
control****
Peptide
number
case****
Zinc-alpha-2-glycoprotein P25311 2 9 2 2
*Uniprot accession numbers that can be found on www.uniprot.org; ** Number of peptides observed by CE-MS analysis and sequenced by LC-MS/MS for each
identified protein; *** Percentage of peptide coverage of the protein sequence; ****, Number of peptides observed by CE-MS and sequenced by LC-MS/MS in controls
or cases.
doi:10.1371/journal.pone.0096895.t002
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Table 3. List of significant regulated proteins.
Protein name
Fold change AMD/
control
Standard
deviation for fold
change p-value adjusted p-value
Ig kappa/lambda chain C region 6.56 13.27 4.58E-06 4.45E-04
Serum albumin 1.91 1.49 3.27E-05 1.58E-03
Ig gamma-1 chain C region 3.14 4.70 6.54E-05 1.74E-03
Antithrombin-III 5.50 12.29 7.16E-05 1.74E-03
Ig lambda-2 chain C regions 4.55 9.94 1.30E-04 2.51E-03
Serotransferrin* 1.74 1.52 3.99E-04 6.45E-03
Afamin 3.28 6.58 1.93E-03 2.16E-02
Histidine-rich glycoprotein 10.85 49.18 2.45E-03 2.16E-02
Retinol-binding protein 3* 2.78 5.51 2.72E-03 2.20E-02
Apolipoprotein A-I* 2.30 3.62 3.88E-03 2.73E-02
Fibrinogen alpha chain 2.90 6.30 3.94E-03 2.73E-02
Ig alpha-1 chain C region 35.34 147.90 2.32E-03 2.16E-02
Alpha-2-HS-glycoprotein 2.58 5.78 1.55E-02 8.70E-02
Transthyretin* 1.74 2.11 1.61E-02 8.70E-02
Prostaglandin-H2 D-isomerase 1.65 1.97 2.33E-02 1.19E-01
Haptoglobin 2.92 7.89 3.34E-02 1.46E-01
Glutathione peroxidase 3 4.26 18.42 3.79E-02 1.51E-01
Alpha-1-antitrypsin* 1.73 2.56 4.04E-02 1.51E-01
Inter-alpha-trypsin inhibitor heavy chain H1 2.34 5.84 4.82E-02 1.67E-01
Legend: Fold change AMD/control. Fold increase or decrease observed in AMD patients compared to controls; p-value - unadjusted p-value (Wilcoxon signed-rank test);
adjusted p-value - p-value corrected for multiple testing (Benjamini and Hochberg method) and expressed in bold, when statistically significant. * proteins selected for
western-blot analysis.
doi:10.1371/journal.pone.0096895.t003
Figure 2. Western blot validation of candidate markers for AMD. Representative Western blots of analysis of expression of selected vitreous
proteins.
doi:10.1371/journal.pone.0096895.g002
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Table 4. Western blot analysis of selected proteins found upregulated in vitreous of AMD patients by CE-MS.
Protein name AMD control P-value Fold change Regulation in proteome analysis
Alpha-1-Antitrypsin 1618.66610.2 689.56174.1 p = 0.02 2.35 q
Apolipoprotein A 1 1925.36404.9 1463.26360.4 p = 0.27 1.32 q
Retinol-binding protein 3 471.9650.9 427.3653.9 p = 0.28 1.10 q
Serotransferrin 1224.16231.1 1059.66247.7 p = 0.25 1.16 q
Transthyretin 1169.86592.8 747.46143.8 p = 0.15 1.57 q
Presented are the results of intensities measured by enhanced chemiluminescence from SDS PAGE Western blots. The mean 6 standard deviation from 4 independent
undiluted vitreous AMD and 4 independent undiluted vitreous control samples is given. P-values were calculated by the Mann-Whitney statistical test.
doi:10.1371/journal.pone.0096895.t004
Figure 3. Bioinformatic analysis of identified biomarkers. A. Gene ontology analysis shows proteins involved in fatty acid binding. platelet
degranulation. serine protease inhibitor activity and hydrogen peroxide catabolic processes. B Interaction network of identified biomarker candidates
involving 18 out of the 19 proteins. Proteins involved in inflammation. acute phase response (including cellular adhesion). signaling via lipid-
mediated pathways (including transport) and activation of proteolytic cascades. as well as transcriptional activity are indicated. Red diamonds
indicate proteins which are significant after correction for multiple testing. and grey ones are the remainder of the query set. Circles indicate gap-
fillers which were added to connect proteins via protein-protein interactions. Direct association between the significant biomarker set are indicated
by a bold line. and relate to immune response (immunoglobulin cluster). protease inhibitor activity. and an activation of the peroxisome proliferator-
activated receptor signaling pathway/CDC42 signal transduction pathway. as suggested through APOA1 interactions. C. Kyoto encyclopedia of genes
and genomes pathway analysis. Statistically relevant biomarker proteins were mapped onto KEGG pathway maps and showed an involvement of
fibril formation and inhibition of fibrinolysis in the coagulation cascade and association with arachidonic acid metabolism.
doi:10.1371/journal.pone.0096895.g003
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representative of the leakage from exudative CNV into the
vitreous. Even though plasma proteins might not be responsible
for the onset of an exudative AMD, their levels might be of
diagnostic value for disease and represent the underlying
pathophysiology of AMD. Future studies are important to identify
which of these proteins are secreted from the abnormal CNV
tissue.
The observed upregulation of a number of proteins in vitreous
of AMD patients provides further insights into the pathophysiol-
ogy of AMD:
Transport proteins
Upregulation of transport proteins such as albumin and
serotransferrin in AMD patients confirms the findings from
previous proteome analyses of anterior chamber fluids [5]. In
addition, further transport proteins like transthyretin and apoli-
poprotein A-I were identified. All of these were upregulated in the
AMD group; all are biologically essential for cell homeostasis
(albumin) and are carriers of hormones like retinol (albumin and
transthyretin) or ions (serotransferrin). It is important to stress that
in chronic diseases, such as AMD, the dysregulation of these
abundant proteins has been observed in serum [33,34], but so far,
their presence in the vitreous has received little attention.
Inflammatory proteins
Immunoglobulin heavy chains and alpha-1-antitrypsin were
upregulated in the AMD samples. Alpha-1-antitrypsin is an acute
phase protein member of the serpin family that inhibits a wide
variety of proteases and thereby protects tissues from enzymes of
inflammatory cells, especially neutrophil elastase. This is the first
time that increased alpha-1-antitrypsin abundance in vitreous has
been associated with AMD. However alpha-1-antitrypsin does not
seem specific for AMD since upregulation of alpha-1-antitrypsin
was observed in both aqueous and blood of patients with glaucoma
[35].
Mediators of coagulation
Fibrinogen is essential during coagulation as it is converted by
plasmin into fibrin, and higher blood levels have been associated
with AMD [36]. Rheopheresis, a treatment that microfilters
fibrinogen from the blood of AMD patients, seems to be protective
in the progression of AMD, however, the approach is controversial
discussed [37]. In this study, we demonstrated that the fibrinogen
alpha chain was upregulated in the AMD group. As for alpha-1-
antitrypsin, although potentially involved in the pathophysiology
of AMD, increased fibrinogen abundance in vitreous is not specific
for AMD since such upregulation was previously also observed in
vitreous samples of patients with diabetic retinopathy [38].
Specific ocular markers
In humans, prostaglandin H2-D isomerase catalyzes the
conversion of prostaglandin H2 to prostaglandin D2, which
functions as a neuromodulator and as a trophic factor in the
central nervous system for fatty acid biosynthesis. Its occurrence
has been described in proliferative diabetic retinopathy; but it has
not been previously associated with AMD [39]. The inter-
photoreceptor retinol binding protein is a large glycoprotein,
located in the extracellular matrix between the RPE and the
photoreceptors. It is known to bind retinoids and is thought to
transport retinoids between the retinal pigment epithelium and the
photoreceptors. Its potential involvement in AMD has recently
been described based on the analysis of blood samples [40,41] and
is confirmed by our findings.
The bioinformatic analyses using GO-term clustering, physical
interaction module assembly, and KEGG pathway data mapping
have shown an involvement of pathways consisting of fatty acid
binding and transport, exocytosis, and protease inhibitory activity,
which are also partially involved in Complement and coagulation
cascades. However, more importantly is the notion that there
appears to be an up-regulation of hydrogen peroxide catabolic
processes, which suggest that oxidative stress is exerted in AMD.
The interactome analysis surprisingly showed a highly inter-
connected network of 18 of the 19 relevant proteins, where only 36
additional molecules were needed to generate a specific molecular
network, suggesting that the up-regulated proteins form a potential
dysregulated functional cluster encompassing immune responses
and complement cascade proteins, protease cascades maybe linked
to the membrane attack complex or possibly to counteract the
enzymatic effect of up-regulated molecules such as GPX3, RBP3
and PTGDS, or as modulators of gene activation cascades. This
unusually high selectivity also argues against the hypothesis that
these proteins are observed in increased abundance merely as a
result of unspecific leakage of plasma proteins, and support the
hypothesis that the increase in these proteins is specifically linked
to AMD.
The up-regulation of GPX3 is of particular interest, since it was
shown previously that cataracts contain elevated levels of oxidants
such as dehydroascorbic acid (DHA), indicative of oxidative stress,
linked to a potentially elevated level of extracellular glutathione
peroxidase GPX3 [42]. Mechanistically, the over-expression is
suggested to result in accumulated oxidants in the glutathion/
ascorbic acid homeostasis cycle, leading to DHA-polymer crystal
formation in the lens as well as potentially toxic breakdown
products of ascorbic acid.
In conclusion, in this study we could demonstrate that a bottom-
up approach combining CE-MS (for protein selection) and LC-
MS/MS (for protein identification) led to the identification of 19
candidate proteins in undiluted vitreous of AMD patients. Even
with the limitations of this study (e.g., demographic matching,
demand for validation in a larger cohort with a wider set of clinical
parameters), the novel information gained from this study of a high
number of undiluted vitreous samples provides additional insight
into the pathophysiology of wet AMD.
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